AU2778099A - Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoformdisorders, dissociative, eating disorders, impulse control disorders and autism - Google Patents
Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoformdisorders, dissociative, eating disorders, impulse control disorders and autism Download PDFInfo
- Publication number
- AU2778099A AU2778099A AU27780/99A AU2778099A AU2778099A AU 2778099 A AU2778099 A AU 2778099A AU 27780/99 A AU27780/99 A AU 27780/99A AU 2778099 A AU2778099 A AU 2778099A AU 2778099 A AU2778099 A AU 2778099A
- Authority
- AU
- Australia
- Prior art keywords
- chloro
- methyl
- tetrahydro
- hydroxy
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3320598A | 1998-03-02 | 1998-03-02 | |
| US09033205 | 1998-03-02 | ||
| PCT/US1999/003721 WO1999044615A1 (en) | 1998-03-02 | 1999-03-01 | Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2778099A true AU2778099A (en) | 1999-09-20 |
Family
ID=21869083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU27780/99A Abandoned AU2778099A (en) | 1998-03-02 | 1999-03-01 | Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoformdisorders, dissociative, eating disorders, impulse control disorders and autism |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1058551A1 (sk) |
| JP (1) | JP2002505291A (sk) |
| KR (1) | KR20010041477A (sk) |
| CN (1) | CN1291893A (sk) |
| AR (1) | AR018297A1 (sk) |
| AU (1) | AU2778099A (sk) |
| BR (1) | BR9908392A (sk) |
| CA (1) | CA2322201A1 (sk) |
| CO (1) | CO4910136A1 (sk) |
| HU (1) | HUP0101057A3 (sk) |
| IL (1) | IL137715A0 (sk) |
| NO (1) | NO20004363L (sk) |
| PE (1) | PE20000333A1 (sk) |
| SK (1) | SK12962000A3 (sk) |
| WO (1) | WO1999044615A1 (sk) |
| ZA (1) | ZA991638B (sk) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410527B1 (en) * | 1998-03-02 | 2002-06-25 | Schering Corporation | Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism |
| RU2374245C1 (ru) | 2008-08-22 | 2009-11-27 | Андрей Александрович Иващенко | Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство |
| PT2872145T (pt) * | 2012-07-12 | 2022-05-26 | Emalex Biosciences Inc | Benzazepinas fundidas para o tratamento da síndrome de tourette |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| EP1043980A2 (en) * | 1997-10-28 | 2000-10-18 | Schering Corporation | Method of reducing craving in mammals |
-
1999
- 1999-03-01 BR BR9908392-2A patent/BR9908392A/pt not_active IP Right Cessation
- 1999-03-01 PE PE1999000169A patent/PE20000333A1/es not_active Application Discontinuation
- 1999-03-01 AU AU27780/99A patent/AU2778099A/en not_active Abandoned
- 1999-03-01 HU HU0101057A patent/HUP0101057A3/hu unknown
- 1999-03-01 IL IL13771599A patent/IL137715A0/xx unknown
- 1999-03-01 CO CO99012525A patent/CO4910136A1/es unknown
- 1999-03-01 CN CN99803496A patent/CN1291893A/zh active Pending
- 1999-03-01 EP EP99908318A patent/EP1058551A1/en not_active Withdrawn
- 1999-03-01 CA CA002322201A patent/CA2322201A1/en not_active Abandoned
- 1999-03-01 WO PCT/US1999/003721 patent/WO1999044615A1/en not_active Application Discontinuation
- 1999-03-01 JP JP2000534217A patent/JP2002505291A/ja not_active Withdrawn
- 1999-03-01 KR KR1020007009634A patent/KR20010041477A/ko not_active Application Discontinuation
- 1999-03-01 ZA ZA9901638A patent/ZA991638B/xx unknown
- 1999-03-01 AR ARP990100860A patent/AR018297A1/es unknown
- 1999-03-01 SK SK1296-2000A patent/SK12962000A3/sk unknown
-
2000
- 2000-09-01 NO NO20004363A patent/NO20004363L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA991638B (en) | 1999-09-01 |
| WO1999044615A1 (en) | 1999-09-10 |
| HUP0101057A3 (en) | 2001-09-28 |
| PE20000333A1 (es) | 2000-05-13 |
| IL137715A0 (en) | 2001-10-31 |
| BR9908392A (pt) | 2000-10-31 |
| CA2322201A1 (en) | 1999-09-10 |
| JP2002505291A (ja) | 2002-02-19 |
| HUP0101057A2 (hu) | 2001-08-28 |
| CO4910136A1 (es) | 2000-04-24 |
| NO20004363L (no) | 2000-10-31 |
| KR20010041477A (ko) | 2001-05-25 |
| NO20004363D0 (no) | 2000-09-01 |
| AR018297A1 (es) | 2001-11-14 |
| SK12962000A3 (sk) | 2001-08-06 |
| EP1058551A1 (en) | 2000-12-13 |
| CN1291893A (zh) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casey | The relationship of pharmacology to side effects | |
| CN103251598A (zh) | 氟班色林在治疗绝经前性欲障碍中的用途 | |
| KR20090103876A (ko) | 호르몬 변화의 증상을 치료 또는 예방하기 위한 방법 | |
| AU2023282336A1 (en) | Pharmaceutical combination comprising a t-type calcium channel blocker | |
| Mamo et al. | Managing antipsychotic-induced parkinsonism | |
| US6410527B1 (en) | Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism | |
| AU2778099A (en) | Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoformdisorders, dissociative, eating disorders, impulse control disorders and autism | |
| KR20010031470A (ko) | 포유동물의 갈망을 감소시키는 방법 | |
| RU2352336C2 (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| EP1613328B1 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| EP1061925B1 (en) | Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist | |
| MXPA00008654A (en) | Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism | |
| CZ20003004A3 (cs) | Použití antagonistů D1/D5 pro léčbu obsesivně kompulzivní choroby, somatoformních chorob, disociativních chorob, poruch příjmu potravy, impulzivních poruch jednání a autismu | |
| Valldeoriola et al. | Therapy of behavioral disorders in Parkinson's disease | |
| CZ27299A3 (cs) | Způsob léčení bipolární afektivní poruchy | |
| Del Zompo et al. | A double-blind study of minaprine versus amitriptyline in major depression | |
| IE903278A1 (en) | Use of dopamine-autoreceptor agonists in the treatment of¹drug dependency | |
| WO2000030639A1 (de) | Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems | |
| Gupta et al. | Side effects of atypical antipsychotics in the geriatric population | |
| Sharpe et al. | Nefazodone in the treatment of patients with post-traumatic stress disorder | |
| CN101304746A (zh) | 氟班色林在治疗绝经前性欲障碍中的用途 | |
| CA2524904A1 (en) | Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration | |
| JP2002515436A (ja) | カリウムチャネル作働薬 | |
| Vet—QN06AF04 | Tranylcypromine Sulfate (rINNM) | |
| Yu et al. | Ziprasidone: A new atypical antipsychotic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |